Original article by Jessica Gardner
The Australian Financial Review – Page: 15 & 20 : 15-May-15

Wilson HTM has changed its recommendation on ResMed from "buy" to "sell" after clinical trials of a sleep apnoea device showed that patients with a heart condition were at greater risk of death when using it. The results of the clinical trial prompted ResMed’s Australian-listed shares to close $A1.52 lower at $A6.73 on 14 May 2015. ResMed notes that the ventilation machine used in the clinical trial accounted for just seven per cent of its revenue in the last financial year.

CORPORATES
RESMED INCORPORATED – ASX RMD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, CREDIT SUISSE (AUSTRALIA) LIMITED, DEUTSCHE BANK AG, UBS HOLDINGS PTY LTD